HUM-MOLGEN events: Pharmacogenomics: the promise and reality of individualized treatment

HUM-MOLGEN -> Events -> Meetings and Conferences

Pharmacogenomics: the promise and reality of individualized treatment

June 20, 2002

Institut Pasteur, Paris, France
October 17-18, 2002

OPENING REMARKS
Welcome to the 2nd EUROCONFERENCE on Pharmacogenomics
Jeffrey M. Drazen, N.E.J.M., Boston, USA
B. Boris Vargaftig, Institut Pasteur, Paris, F

CANCER

Genetic polymorphisms and toxicity/response to cytotoxics
Mark J. Ratain, University of Chicago, USA

The clinical value of pharmacogenetics in Tamoxifen therapy
David A. Flockhart, Indiana University School of Medicine, Indianapolis, USA

Expression profiling: learning to search for things unappreciated
Stephen H. Friend, Rosetta Inpharmatics, Kirkland, USA

Gene expression profiles in diffuse large B-cell lymphoma
Margaret Shipp, Dana-Farber Cancer Institute, Boston, USA

Applications for protein and antibody arrays in pharmacoproteomics
Ian Humphery-Smith, Glaucus Proteomics, Bunnik, NL

ADVANCES IN GENOMICS OF CNS DISEASES

Pharmacogenomics of major depression and antidepressant treatment
Julio Licinio, University of California, Los Angeles, USA

Pharmacogenetic strategies in bipolar disorder
Gustavo Turecki, McGill University, Verdun, CDN

Genetic prediction of response and side effects from psychiatric medications
Vincenzo S. Basile, Mario Masellis & James L. Kennedy, University of Toronto, CDN

Advances in the pharmacogenetic prediction of antipsychotic response
Robert Kerwin, Institute of Psychiatry, London, UK

Pharmacogenomics and pharmacogenetics of Alzheimer's disease, toward new targets
Philippe Amouyel, Institut Pasteur de Lille, F

Pharmacogenetics in the therapy of epilepsy
Ulrich Brinkmann, Epidauros Biotechnologie, Bernried, D

FRIDAY OCTOBER 18, 2002

CARDIOVASCULAR DISEASES

Analytical strategies to understand how genetics contributes to common cardiovascular disorders
François Cambien, INSERM U525/SC7, Paris, F

Gene-environment interaction in coronary artery disease
Steve E. Humphries, Royal Free & University College London Medical School, UK

Lipid lowering responses modified by genetic variation
Bernhard R. Winkelmann, University of Heidelberg, D

Antihypertensive pharmacogenetics
Stephen T. Turner, Mayo Clinic, Rochester, USA

Drug target pharmacogenomics: complexity of the drug response
Julie A. Johnson, University of Florida, Gainesville, USA

IMMUNOLOGY, ALLERGY, METABOLIC/OBESITY

Osteoporosis pharmacogenetics
John A. Eisman, Garvan Institute of Medical Research, Sydney, AUS

Pharmacogenetics of alcoholism and substance abuse
David Goldman, NIAAA, NIH, Rockville, USA

Pharmacogenomics in anesthesia and analgesia
Evan Kharash, University of Washington, Seattle, USA

Individualized treatment of obesity: fact or fiction?
Arya M. Sharma, University of Berlin, D

Genetically variable nicotine inactivation: potential role in smoking and therapeutic approaches
Rachel Tyndale, University of Toronto, CDN

Gene expression profiling in toxicology
Françoise de Longueville, University of Namur, B

Organized by:

Institut Pasteur Euroconferences & The New England Journal of Medicine

Invited Speakers:

Mark J. Ratain, University of Chicago, USA
David A. Flockhart, Indiana University School of Medicine, Indianapolis, USA
Stephen H. Friend, Rosetta Inpharmatics, Kirkland, USA
Margaret Shipp, Dana-Farber Cancer Institute, Boston, USA
Ian Humphery-Smith, Glaucus Proteomics, Bunnik, NL
Gustavo Turecki, McGill University, Verdun, CDN
Vincenzo S. Basile, Mario Masellis & James L. Kennedy, University of Toronto, CDN
Robert Kerwin, Institute of Psychiatry, London, UK
Philippe Amouyel, Institut Pasteur de Lille, F
Ulrich Brinkmann, Epidauros Biotechnologie, Bernried, D
François Cambien, INSERM U525/SC7, Paris, F
Steve E. Humphries, Royal Free & University College London Medical School, UK
Bernhard R. Winkelmann, University of Heidelberg, D
Stephen T. Turner, Mayo Clinic, Rochester, USA
Julie A. Johnson, University of Florida, Gainesville, USA
John A. Eisman, Garvan Institute of Medical Research, Sydney, AUS
David Goldman, NIAAA, NIH, Rockville, USA
Evan Kharasch, University of Washington, Seattle, USA
Arya M. Sharma, University of Berlin, D
Rachel Tyndale, University of Toronto, CDN
Françoise de Longueville, University of Namur, B

Deadline for Abstracts:

2002-08-14

Registration:

Industrial rate : 1100 euros VAT excluded
Academic rate : 458 euros VAT excluded

E-mail:

euroconf@pasteur.fr

Posted by:

Ludovic Drye

Host:

cache.pasteur.fr